1. Developments in the Wet AMD Treatment Landscape

3. This program will include a discussion of off-label treatment, investigational agents and devices not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Current Treatments for Wet AMD Pan-VEGF-A Blockers

5. How Effective Are Current Treatments?

6. Treatment Approaches Impacts of Individualized vs Monthly Treatments

7. Individualized Treatment Strategies in Practice

8. Challenge of Undertreatment

9. Seeking Better Outcomes Diagnostic Tests: PHP

10. Seeking Better Outcomes Diagnostic Tests: OCTA

11. Challenge of Treating Refractory Wet AMD

12. Unmet Needs Patient Improvement and Therapeutic ‘Wish List’

13. Emerging Treatments Therapeutic Targets

14. New and Emerging Anti-VEGF Blockers

15. Brolucizumab Phase 3 Studies: HAWK and HARRIER

16. Abicipar

17. Conbercept

18. OPT-302

19. ICON-1

20. Anti-Angiopoetin-2 Agents

21. TKIs: Therapeutic Swing and Miss?

22. Integrin Antagonists

23. Sustained Delivery Methods PDS

24. Sustained Delivery Method Injectable Delivery

25. Gene Therapy

26. Gene Therapy (cont)

27. Is Prevention Possible?

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)